A Study of ABBV-383 with Anti-Cancer Drugs in People with Multiple Myeloma


Full Title

A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma


ABBV-383 is a bispecific antibody that targets a protein called BCMA on multiple myeloma cells. Researchers want to find the best dose of ABBV-383 to use in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even with treatment. ABBV-383 binds to two different proteins: one on cancer cells and one on immune cells. It may help your immune system fight cancer cells by teaching your own cells to destroy the tumor.

Giving ABBV-383 with the drugs daratumumab, dexamethasone, lenalidomide, pomalidomide, or nirogacestat may be better than ABBV-383 alone. If you join this study, you will get one of these treatments:

  • ABBV-383 with pomalidomide and dexamethasone
  • ABBV-383 with lenalidomide and dexamethasone
  • ABBV-383 with daratumumab and dexamethasone
  • ABBV-383 with nirogacestat

ABBV-383 is given intravenously (by vein). Daratumumab is given through an injection under the skin. The other drugs are taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have multiple myeloma that keeps growing even after treatment.
  • Have recovered from the serious side effects of previous therapies.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Malin Hultcrantz’s office at 646-608-3714.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID